glucose, (beta-d)-isomer has been researched along with MODS in 113 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (5.31) | 18.7374 |
1990's | 30 (26.55) | 18.2507 |
2000's | 51 (45.13) | 29.6817 |
2010's | 25 (22.12) | 24.3611 |
2020's | 1 (0.88) | 2.80 |
Authors | Studies |
---|---|
Alexis, A; Carrer, DP; Giamarellos-Bourboulis, EJ; Kotsaki, A; Louis, K; Mylona, V; Netea, MG; Pistiki, A; Roditis, K; Savva, A; Van der Meer, JW | 1 |
Brown, GD; Engstad, R; Hoving, JC; Marakalala, MJ; Netea, MG; Williams, DL | 1 |
Goss, KL; Hilkin, BM; Hook, JS; Moreland, JG; Newell, EA; Whitmore, LC | 1 |
Huang, Z; Liu, C; Liu, S; Liu, Y; Pang, Q; Song, S; Wu, Q; Zhang, J; Zhang, R | 1 |
Guo, H; Liu, Q; Lu, J; Tian, G; Wang, H | 1 |
Jin, Y; Liu, Q; Lu, J; Lv, Y; Zhao, M | 1 |
Bai, XD; Hu, S; Li, JY; Li, YM; Wang, HB; Zhao, ZK; Zheng, JG | 1 |
Chen, W; Liu, C; Liu, S; Miao, R; Pang, Q; Song, S; Zhang, J; Zhou, Y | 1 |
Armstrong, MG; Hall, JV; Hoover, DB; Li, C; Monroe, LL; Ozment, TR; Williams, DL; Zhang, X | 1 |
Bramanti, P; Crisafulli, C; Cuzzocrea, S; Di Paola, R; Esposito, E; Genovese, T; Mazzon, E; Salvemini, D | 1 |
Dimitrova, P; Ivanovska, N | 1 |
Avsar, FM; Berkem, H; Guc, MO; Guler, G; Hengirmen, S; Iskit, AB; Ozel, H; Yuksel, BC | 1 |
Hou, L; Ji, G; Li, N; Li, S; Lu, Y; Ma, S; Peng, D; Qin, M; Shang, L; Xie, K; Xiong, L | 1 |
Bramanti, P; Cuzzocrea, S; Di Paola, R; Galuppo, M; Mazzon, E; Paterniti, I | 1 |
Li, ZH; Lu, JY; Lü, Y; Yang, Y; Zhao, M | 1 |
Hendriks, T; Joosten, LA; Kullberg, BJ; Netea, MG; van de Veerdonk, FL; van der Meer, JW; Verschueren, IC | 1 |
Hou, L; Ji, G; Li, J; Lu, Y; Mu, J; Peng, D; Shang, L; Xie, K; Xiong, L | 1 |
Hou, L; Liu, W; Pei, Y; Wang, G; Xie, K; Xiong, L; Yu, Y; Zhang, Z | 1 |
Guan, Y; Liu, M; Liu, X; Yang, Q; Zhang, L | 1 |
Bramanti, P; Cuzzocrea, S; Di Paola, R; Esposito, E; Impellizzeri, D; Mazzon, E | 1 |
Ashton, SH; Borg, KT; Cook, JA; Fan, H; Halushka, PV; Wong, D | 1 |
Capuano, A; Cuzzocrea, S; Di Palma, D; Donniacuo, M; Esposito, E; Mazzon, E; Paterniti, I; Rinaldi, B; Rossi, F; Sodano, L | 1 |
Aloisi, C; Cuzzocrea, S; Galuppo, M; Italiano, D; Mazzon, E; Mondello, P; Mondello, S | 1 |
Capuano, A; Cuzzocrea, S; Di Palma, D; Di Paola, R; Donniacuo, M; Imperatore, F; Mazzon, E; Rinaldi, B; Rossi, F; Sodano, L | 1 |
Bramanti, P; Cuzzocrea, S; Di Paola, R; Impellizzeri, D; Mazzon, E; Paterniti, I | 1 |
Bruscoli, S; Cuzzocrea, S; Di Paola, R; Esposito, E; Galuppo, M; Mazzon, E; Nocentini, G; Riccardi, C; Riccardi, L; Ronchetti, S | 1 |
Kang, JR; Li, F; Lu, JY; Tian, G; Wang, HW; Wang, XH; Yang, W; Yang, Y | 1 |
Guo, H; Li, F; Liu, Q; Lu, JY; Wang, HW | 1 |
Goris, RJ; Hendriks, T; van de Loo, FA; van der Jagt, M; Volman, TJ | 1 |
Barbera, A; Caputi, AP; Centorrino, T; Chatterjee, PK; Ciccolo, A; Cuzzocrea, S; Dugo, L; Fulia, F; Mazzon, E; McDonald, MC; Serraino, I; Thiemermann, C | 1 |
Hristova, M; Ivanovska, N; Yordanov, M | 1 |
Lan, C; Tang, CW | 1 |
Hu, S; Jiang, XG; Jin, H; Li, JY; Lu, JY; Lü, Y; Sheng, ZY; Zhang, R | 1 |
Hu, S; Lu, JY; Sun, Y; Tong, X; Wang, XH; Yang, Y | 1 |
Caputi, AP; Chatterjee, PK; Cuzzocrea, E; Cuzzocrea, S; Di Paola, R; Fulia, F; Genovese, T; Ianaro, A; Patel, NS; Pisano, B; Rossi, A; Sautebin, L; Thiemermann, C | 1 |
Senftleben, U | 1 |
Blask, D; Dauchy, R; Dietz, PA; Lynch, D; Reynolds, FD; Zuckerman, R | 1 |
Caputi, AP; Cuzzocrea, E; Cuzzocrea, S; Di Paola, R; Dugo, L; Fulia, F; Genovese, T; Mazzon, E; Salvemini, D; Serraino, I | 1 |
Caputi, AP; Chatterjee, PK; Cuzzocrea, E; Cuzzocrea, S; Di Paola, R; Di Rosa, M; Dugo, L; Fulia, F; Genovese, T; Ianaro, A; Patel, NS; Pisano, B; Thiemermann, C | 1 |
Caputi, AP; Cuzzocrea, S; De Angelis, A; Filippelli, A; Imperatore, F; Liguori, G; Luongo, C; Rossi, F; Scafuro, A | 1 |
Caputi, AP; Catalano, P; Cuzzocrea, S; Di Paola, R; Genovese, T; Li, JH; Massuda, E; Xu, W; Zhang, J | 1 |
Goris, RJ; Hendriks, T; van der Meer, JW; Volman, TJ | 1 |
Britti, D; Caputi, AP; Cuzzocrea, S; De Sarro, A; Di Paola, R; Dugo, L; Genovese, T; Rossi, A; Sautebin, L; Sciarra, G; Serraino, I | 1 |
DeGroot, J; Goris, RJ; Hendriks, T; Lomme, RM; Verhofstad, AA; Volman, TJ | 1 |
Pallister, I; Topley, N | 1 |
Lan, C; Liu, R; Tang, CW | 1 |
Goris, RJ; Hendriks, T; Volman, TJ | 2 |
Guc, MO; Guler, G; Iskit, AB; Korkmaz, A; Rasa, K; Tanriverdi, P; Yuksel, BC | 1 |
Marshall, JC | 1 |
Phelps, DS; Thomas, NJ; Umstead, TM | 1 |
Lan, C; Liu, R; Tang, C; Wang, C | 1 |
Autore, G; Britti, D; Cuzzocrea, S; Di Paola, R; Genovese, T; Marzocco, S; Mazzon, E; Pinto, A | 1 |
Chen, XM; Du, XG | 1 |
Abouhamze, A; Efron, PA; Hutchins, B; LaFace, D; McAuliffe, PF; Moldawer, LL; Murday, ME; Scumpia, PO; Tannahill, CL; Ungaro, R | 1 |
Qian, X; Wang, S; Xu, B; Xue, Q; Yang, J; Yin, T; Zhu, Q | 1 |
Crisafulli, C; Cuzzocrea, S; Di Bella, P; Di Paola, R; Esposito, E; Genovese, T; Mazzon, E; Meli, R; Menegazzi, M; Muià, C; Suzuki, H | 1 |
Chouker, A; Hoelzl, A; Hummel, T; Kaufmann, I; Peter, K; Schliephake, F; Thiel, M | 1 |
Capuano, A; Cuzzocrea, S; De Lucia, D; Filippelli, A; Imperatore, F; Liguori, G; Rinaldi, B; Rossi, F; Sessa, M | 1 |
Crisafulli, C; Cuzzocrea, S; Di Paola, R; Esposito, E; Genovese, T; Malleo, G; Mazzon, E; Meli, R; Muià, C; Sessa, E | 1 |
Thiemermann, C | 1 |
Li, L; Lu, JY; Tian, G; Wang, HW; Wang, XH; Yang, Y | 1 |
Caminiti, R; Cuzzocrea, S; Di Bella, P; Di Paola, R; Esposito, E; Genovese, T; Malleo, G; Mazzon, E; Muià, C | 1 |
Bramanti, P; Caminiti, R; Cuzzocrea, S; Di Paola, R; Esposito, E; Genovese, T; Malleo, G; Mazzon, E | 1 |
Gilligan, L; Johnson, KJ; Rodriguez, JL; Shayevitz, JR; Tait, AR | 1 |
Goris, RJ; Hendriks, T; Meyer, MP; Nieuwenhuijzen, GA | 1 |
Consalvo, M; De Gaudio, AR; Di Filippo, A; Novelli, GP; Paternostro, E; Pellegrini, G; Scardi, S | 1 |
Chaudry, IH; Deitch, EA; Ertel, W; Mainous, MR | 1 |
Goris, RJ; Hendriks, T; Jansen, MJ; van der Meer, JW; Vogels, MT | 1 |
Dwenger, A; Grotz, M; Gruner, A; Jochum, M; Pape, HC; Regel, G; Remmers, D; Scharff, H | 1 |
Goris, RJ; Hendriks, T; Huyben, CM; Jansen, MJ; Tax, WJ; van der Meer, JW | 1 |
Corstens, FH; Goris, RJ; Hendriks, T; Knapen, MF; Nieuwenhuijzen, GA; Oyen, WJ | 1 |
Cook, DN; Kotwal, GJ; Miller, CG | 1 |
Goris, RJ; Hendriks, T; Knapen, MF; Nieuwenhuijzen, GA; van Rooijen, N | 1 |
Cuzzocrea, S; Flower, RJ; Getting, SJ; Lim, LH; Perretti, M; Salzman, AL; Szabó, C; Zingarelli, B | 1 |
Calapai, G; Campo, GM; Caputi, AP; Costantino, G; Crisafulli, C; Cuzzocrea, S; Di Rosa, M; Nava, F; Rizzo, A; Sautebin, L; Zingarelli, B | 1 |
Geeraedts, LM; Goris, RJ; Hendriks, T; Jansen, MJ; Lange, W; Verhofstad, AA | 1 |
Chiara, O; Fattori, L; Padalino, P; Ravizzini, C; Tiberio, G; Turconi, MG | 1 |
Goris, RJ; Hendriks, T; Jansen, MJ; Knapen, MF; van der Meer, JW; van Kempen, LC | 1 |
Dwenger, A; Grotz, M; Pape, HC; Remmers, D; Tscherne, H; Vaske, R; Wisner, D | 1 |
Bridges, CD; Cone, JB; Ferrer, TJ; Palmer, HE; Robertson, RD; Wallace, BH; Webb, JW | 1 |
Goris, RJ; Hendriks, T; Hermsen, R; Jansen, MJ; Van der Meer, JW | 1 |
Caputi, AP; Ciriaco, E; Costantino, G; Cuzzocrea, S; de Sarro, A; de Sarro, G; Laurà, R; Mazzon, E | 1 |
Caputi, AP; Costantino, G; Cuzzocrea, S; Mazzon, E | 1 |
Caputi, AP; Costantino, G; Cuzzocrea, S; Sottile, A; Teti, D; Zingarelli, B | 1 |
de Man, BM; Goris, RJ; Hendriks, T; Jansen, MJ; van der Meer, JW | 1 |
Cheadle, WG; Daly, J; Kotwal, GJ; Mahesh, J | 1 |
Caputi, AP; Costantino, G; Cuzzocrea, S; Filippelli, A; Imperatore, F; Luongo, C; Mangoni, G; Mazzon, E; Rossi, F; Scafuro, MA | 1 |
Jackson, RJ; Johnson, DD; Maxson, RT; Smith, SD; Thomas, R | 1 |
Burdon, D; Pfeffer, K; Tiedje, T; Vollmer, E; Zabel, P | 1 |
Carcillo, JA; Herzer, WA; Jackson, EK; Mi, Z; Thomas, NJ | 1 |
Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Filipe, HM; Lepore, V; Mazzon, E; McDonald, MC; Terranova, ML; Thiemermann, C | 1 |
deBoisblanc, B; Kantrow, SP; Taylor, DE | 1 |
Barbera, A; Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Dugo, L; Fonti, MT; Mazzon, E | 1 |
Andersson, R; Deng, X; Lasson, A; Soltesz, V; Sun, TZ; Wang, X | 1 |
Chen, H; Guan, F; Wu, X | 1 |
Goris, RJ; Hendriks, T; Kullberg, BJ; Verhofstad, AA; Volman, TJ | 1 |
Caputi, AP; Chatterjee, PK; Cuzzocrea, S; Dugo, L; Fulia, F; Mazzon, E; McDonald, MC; Paola, RD; Thiemermann, C | 1 |
Goris, RJ; Koldewijn, EL; Lieners, CF; Redl, H; van Bebber, IP | 1 |
Lu, JY | 2 |
Goris, RJ; Koopman, JP; Mollen, RM; van Bebber, IP | 1 |
Berg, RD; Deitch, EA; Ma, L; Ma, WJ; Specian, RD | 1 |
Bahrami, S; Goris, RJ; Lieners, C; Redl, H; Schlag, G; van Bebber, IP | 1 |
Bahrami, S; Boekholz, WK; Dinges, HP; Goris, RJ; Redl, H; Schillings, PH; Schlag, G; van Bebber, IP | 1 |
Baxter, J; Bitzer, L; Flynn, W; Gutierrez, C; Kelley, K; Lalka, D; Sands, A; Sharma, P; Steinberg, S; van Liew, J | 1 |
Goris, RJ; Schillings, PH; Speekenbrink, RG; van Bebber, IP | 1 |
Betti, S; Borrelli, E; Chiara, O; Giomarelli, PP; Nespoli, A; Padalino, P | 1 |
Fry, DE; Naff, GB; Schirmer, JM; Schirmer, WJ | 1 |
Boekholtz, WK; Goris, RJ; Nuytinck, JK; Schillings, PH; van Bebber, IP | 1 |
Aboudara, M; Akin, EE; Ambery, P; Barroso, WKS; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Feitosa, ADM; Fonseca, A; Furtado, RHM; Garla, V; Gasparyan, SB; Gordon, RA; Gosch, K; Hoffmann Filho, CR; Jaeger, CP; Javaheri, A; Koch, GG; Kosiborod, MN; Langkilde, AM; Lazcano Soto, JR; Leaes, PE; Martinez, F; Moia, DDF; Mukhtar, O; Nassif, M; Nigro Maia, L; Oscarsson, J; Pursley, M; Silveira, FS; Soares, RVP; Tang, F; Verma, S; Windsor, SL | 1 |
Cai, S; Chen, Z; Gao, Y; Li, T; Xu, S; Zeng, Z; Zhang, J; Zhao, KS | 1 |
Huang, QB | 1 |
3 review(s) available for glucose, (beta-d)-isomer and MODS
Article | Year |
---|---|
NF-kappaB in critical diseases: a bad guy?
Topics: Animals; Antioxidants; Critical Illness; Disease Models, Animal; Gene Expression Regulation; Homeostasis; Humans; Inflammation; Mice; Multiple Organ Failure; NF-kappa B; Oxidation-Reduction; Proline; Signal Transduction; Thiocarbamates; Time Factors; Transcription Factors; Zymosan | 2003 |
Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome.
Topics: Animals; Complement System Proteins; Cytokines; Disease Models, Animal; Humans; Inflammation; Mice; Models, Biological; Multiple Organ Failure; Oxidants; Rats; Time Factors; Zymosan | 2005 |
Classical corticosteroids and new lipid peroxidation inhibitors in the therapy of multiple organ failure (MOF).
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antioxidants; Clinical Trials as Topic; Free Radical Scavengers; Humans; Injections, Intraperitoneal; Lipid Peroxidation; Methylprednisolone; Multiple Organ Failure; Pregnatrienes; Prospective Studies; Rabbits; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Sepsis; Shock, Septic; Zymosan | 1997 |
1 trial(s) available for glucose, (beta-d)-isomer and MODS
Article | Year |
---|---|
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Benzhydryl Compounds; Cardiometabolic Risk Factors; COVID-19; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Multiple Organ Failure; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
109 other study(ies) available for glucose, (beta-d)-isomer and MODS
Article | Year |
---|---|
Bacterial translocation in an experimental model of multiple organ dysfunctions.
Topics: Animals; Bacterial Translocation; Disease Models, Animal; Enterobacteriaceae; Enterococcus; Interferon-gamma; Interleukin-10; Interleukin-17; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Spleen; Zymosan | 2013 |
Dectin-1 plays a redundant role in the immunomodulatory activities of β-glucan-rich ligands in vivo.
Topics: Animals; Disease Models, Animal; Glucans; Lectins, C-Type; Ligands; Mice; Multiple Organ Failure; Staphylococcal Infections; Staphylococcus aureus; Zymosan | 2013 |
NOX2 protects against progressive lung injury and multiple organ dysfunction syndrome.
Topics: Animals; Bone Marrow Cells; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Lung; Lung Injury; Macrophage Activation; Macrophages; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Organ Failure; NADPH Oxidase 2; NADPH Oxidases; Neutrophil Infiltration; Systemic Inflammatory Response Syndrome; Zymosan | 2014 |
Role of Serotonin in MODS: Deficiency of Serotonin Protects Against Zymosan-Induced Multiple Organ Failure in Mice.
Topics: 5-Hydroxytryptophan; Animals; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Fenclonine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Organ Failure; Oxidative Stress; Peritonitis; Protective Agents; Serotonin; Shock; Tryptophan Hydroxylase; Zymosan | 2015 |
Protective effect of Flt3L on organ structure during advanced multiorgan dysfunction syndrome in mice.
Topics: Adjuvants, Immunologic; Animals; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Male; Membrane Proteins; Mice, Inbred C57BL; Multiple Organ Failure; Zymosan | 2015 |
PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.
Topics: Animals; B7-H1 Antigen; Cell Proliferation; Cytokines; Dendritic Cells; Lymphocyte Activation; Mice; Multiple Organ Failure; Spleen; T-Lymphocytes; Zymosan | 2015 |
Dimethyl sulfoxide inhibits zymosan-induced intestinal inflammation and barrier dysfunction.
Topics: Amine Oxidase (Copper-Containing); Animals; Apoptosis; Dimethyl Sulfoxide; Enteritis; Free Radical Scavengers; Interleukin-10; Intestinal Mucosa; Male; Malondialdehyde; Multiple Organ Failure; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Superoxide Dismutase; Systemic Inflammatory Response Syndrome; Tight Junctions; Tumor Necrosis Factor-alpha; Zonula Occludens-1 Protein; Zymosan | 2015 |
THE PROTECTIVE ROLE OF CURCUMIN IN ZYMOSAN-INDUCED MULTIPLE ORGAN DYSFUNCTION SYNDROME IN MICE.
Topics: Animals; Anti-Infective Agents; Curcumin; Inflammation; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Zymosan | 2016 |
Zymosan-Induced Peritonitis: Effects on Cardiac Function, Temperature Regulation, Translocation of Bacteria, and Role of Dectin-1.
Topics: Alarmins; Animals; Disease Models, Animal; Inflammation; Lectins, C-Type; Male; Mice; Mice, Knockout; Multiple Organ Failure; Peritonitis; Receptors, Pattern Recognition; Zymosan | 2016 |
Fumonisin b1 reduces the development of multiple organ failure induced by zymosan in mice.
Topics: Animals; Cytokines; Fumonisins; Immunohistochemistry; Inflammation; Male; Mice; Multiple Organ Failure; Nitric Oxide; Peritonitis; Peroxidase; Shock; Time Factors; Treatment Outcome; Zymosan | 2009 |
Tyrphostin AG-490 inhibited the acute phase of zymosan-induced inflammation.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bilirubin; Creatinine; Inflammation; Interleukin-6; Macrophages; Male; Mice; Multiple Organ Failure; Nitric Oxide; Nitric Oxide Synthase Type II; Protein Kinase Inhibitors; STAT Transcription Factors; Tumor Necrosis Factor-alpha; Tyrphostins; Whole Blood Coagulation Time; Zymosan | 2008 |
The effects of L-NG-nitroarginine in a zymosan-induced multiple organ dysfunction syndrome model.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Kidney; Male; Mice; Multiple Organ Failure; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Pancreas; Splanchnic Circulation; Zymosan | 2009 |
Effects of reactive oxygen species scavenger on the protective action of 100% oxygen treatment against sterile inflammation in mice.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Cytokines; Free Radical Scavengers; Heart; Inflammation; Kidney; Liver; Lung; Male; Mice; Multiple Organ Failure; Myocardium; Oxygen; Reactive Oxygen Species; Sepsis; Thiourea; Zymosan | 2010 |
PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice.
Topics: Acute Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Adhesion Molecules; Cytokines; Fas Ligand Protein; Flavonoids; I-kappa B Proteins; Inflammation Mediators; Male; Mice; Mitogen-Activated Protein Kinases; Multiple Organ Failure; Neutrophil Infiltration; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Peritonitis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Systemic Inflammatory Response Syndrome; Time Factors; Transcription Factor RelA; Tyrosine; Zymosan | 2010 |
Relationship between HMGB1 content and MHC-II expression in circulating monocytes and spleen of mice challenged with zymosan.
Topics: Animals; Histocompatibility Antigens Class II; HMGB1 Protein; Male; Mice; Mice, Inbred C57BL; Monocytes; Multiple Organ Failure; Spleen; Zymosan | 2009 |
Differential effects of IL-17 pathway in disseminated candidiasis and zymosan-induced multiple organ failure.
Topics: Animals; Candidiasis; Enzyme-Linked Immunosorbent Assay; Interferon-gamma; Interleukin-10; Interleukin-17; Mice; Mice, Knockout; Multiple Organ Failure; Phagocytosis; Signal Transduction; Tumor Necrosis Factor-alpha; Zymosan | 2010 |
Subanesthetic dose of isoflurane protects against zymosan-induced generalized inflammation and its associated acute lung injury in mice.
Topics: Acute Lung Injury; Amitrole; Animals; Catalase; Inflammation; Isoflurane; Male; Mice; Multiple Organ Failure; Oxidative Stress; Superoxide Dismutase; Zymosan | 2010 |
Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model.
Topics: Administration, Inhalation; Animals; Antioxidants; Biomarkers; Cytokines; Dinoprost; Drug Evaluation, Preclinical; Gases; HMGB1 Protein; Hydrogen; Inflammation; Male; Mice; Mice, Inbred ICR; Multiple Organ Failure; Oxidation-Reduction; Superoxide Dismutase; Viscera; Zymosan | 2010 |
Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats.
Topics: Animals; Cytoprotection; Female; Glycoproteins; Intercellular Adhesion Molecule-1; Kidney; Liver; Lung; Male; Multiple Organ Failure; Rats; Rats, Wistar; Survival Analysis; Toll-Like Receptor 4; Trypsin Inhibitors; Tumor Necrosis Factor-alpha; Zymosan | 2010 |
Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amylases; Animals; Apoptosis; Ascitic Fluid; Aspartate Aminotransferases; bcl-2-Associated X Protein; Bicarbonates; Bilirubin; Blood Gas Analysis; Body Weight; Cell Count; Creatinine; Fas Ligand Protein; Hydrogen-Ion Concentration; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-1beta; Kidney; Lipase; Liver; Lung; Male; Mice; Mice, Inbred Strains; Multiple Organ Failure; Nitrates; Nitrites; P-Selectin; Pancreas; Phosphodiesterase 3 Inhibitors; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyridones; Survival Analysis; Tumor Necrosis Factor-alpha; Tyrosine; Zymosan | 2011 |
Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation.
Topics: Animals; Chemokine CXCL12; Disease Models, Animal; Endotoxemia; Interleukin-10; Interleukin-6; Lipopolysaccharides; Macrophages; Male; Mice; Multiple Organ Failure; Receptors, CXCR4; Sepsis; Systemic Inflammatory Response Syndrome; Tumor Necrosis Factor-alpha; Zymosan | 2012 |
PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestines; Kidney; Liver; Lung; Mice; Mice, Knockout; Multiple Organ Failure; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; PPAR alpha; Shock; Simvastatin; Tumor Necrosis Factor-alpha; Up-Regulation; Zymosan | 2011 |
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Cytokines; Enzyme Activation; Fas Ligand Protein; Gene Expression Regulation; Glutamine; Inflammation; Lipid Peroxidation; Male; Mice; Multiple Organ Failure; Neutrophil Infiltration; Nitric Oxide; Peritoneal Cavity; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerases; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Tyrosine; Zymosan | 2011 |
Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.
Topics: Analysis of Variance; Animals; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hyperbaric Oxygenation; Immunohistochemistry; Interleukin-1beta; Male; Multiple Organ Failure; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Zymosan | 2011 |
Effect of NADPH-oxidase inhibitors in the experimental model of zymosan-induced shock in mice.
Topics: Acetophenones; Animals; Apoptosis; Cytokines; Enzyme Inhibitors; Male; Mice; Multiple Organ Failure; NADPH Oxidases; Nitrates; Nitrites; Onium Compounds; Reactive Oxygen Species; Shock; Systemic Inflammatory Response Syndrome; Zymosan | 2011 |
GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.
Topics: Animals; Cell Adhesion Molecules; Gene Deletion; Glucocorticoid-Induced TNFR-Related Protein; Immunohistochemistry; Interleukin-1beta; Interleukin-6; Male; Mice; Mice, Knockout; Multiple Organ Failure; Nitrates; Nitrites; Peroxidase; Recombinant Fusion Proteins; Tumor Necrosis Factor-alpha; Zymosan | 2011 |
Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice.
Topics: Animals; Antigens, CD; Body Weight; Dendritic Cells; fms-Like Tyrosine Kinase 3; Interleukin-10; Interleukin-12; Ligands; Lung; Lung Injury; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Multiple Organ Failure; Survival Rate; Zymosan | 2012 |
Altered MARCH1 ubiquination-regulated dendritic cell immune functions during the early stage of zymosan-induced multiple organ dysfunction syndrome (MODS) in mice.
Topics: Animals; CD11c Antigen; Dendritic Cells; Disease Models, Animal; Disease Progression; Gene Expression; Histocompatibility Antigens Class II; Lymphocyte Activation; Male; Mice; Multiple Organ Failure; Proteasome Endopeptidase Complex; Proteolysis; RNA Interference; Spleen; T-Lymphocytes; Ubiquitin-Protein Ligases; Ubiquitination; Zymosan | 2013 |
Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase.
Topics: Animals; Guanidines; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Nitric Oxide Synthase; Random Allocation; Zymosan | 2002 |
Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat.
Topics: Animals; Calpain; Cell Movement; Cyclooxygenase 2; Dose-Response Relationship, Drug; Glycoproteins; Immunohistochemistry; Intestinal Mucosa; Intestines; Isoenzymes; Liver; Lung; Male; Malondialdehyde; Multiple Organ Failure; Neutrophils; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peritoneum; Peritonitis; Peroxidase; Peroxynitrous Acid; Poly Adenosine Diphosphate Ribose; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Tyrosine; Zymosan | 2002 |
Effect of fangchinoline in murine models of multiple organ dysfunction syndrome and septic shock.
Topics: Alkaline Phosphatase; Alkaloids; Animals; Benzylisoquinolines; Complement System Proteins; Escherichia coli Infections; Liver; Macrophages, Peritoneal; Male; Mice; Mice, Inbred ICR; Multiple Organ Failure; Organ Size; Shock, Septic; Spleen; Time Factors; Tumor Necrosis Factor-alpha; Zymosan | 2003 |
[Increasing activity of the intestinal mucosal mast cells in rats with multiple organ failure].
Topics: Animals; Female; Histamine; Intestinal Mucosa; Mast Cells; Multiple Organ Failure; Rats; Tumor Necrosis Factor-alpha; Zymosan | 2003 |
[A small dose of intraperitoneal injection of zymosan induces systemic inflammatory response and multiple organ dysfunction following gut ischemia-reperfusion injury].
Topics: Animals; Disease Models, Animal; Male; Multiple Organ Failure; Rats; Rats, Wistar; Reperfusion Injury; Systemic Inflammatory Response Syndrome; Zymosan | 2003 |
[Replication of animal model and pathological study of delayed multiple organ dysfunction syndrome in mice].
Topics: Animals; Disease Models, Animal; Male; Mice; Mice, Inbred Strains; Multiple Organ Failure; Zymosan | 2003 |
Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice.
Topics: Animals; Antioxidants; Blotting, Western; Chemotaxis, Leukocyte; Disease Models, Animal; Drug Evaluation, Preclinical; Immunohistochemistry; Lipid Peroxidation; Male; Malondialdehyde; Mice; Mice, Inbred Strains; Multiple Organ Failure; Neutrophils; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxidase; Poly(ADP-ribose) Polymerases; Pyrrolidines; Random Allocation; Thiocarbamates; Time Factors; Tyrosine; Zymosan | 2003 |
The pineal gland hormone melatonin improves survival in a rat model of sepsis/shock induced by zymosan A.
Topics: Animals; Disease Models, Animal; Male; Melatonin; Multiple Organ Failure; Rats; Rats, Sprague-Dawley; Sepsis; Shock; Zymosan | 2003 |
Protective effects of M40401, a selective superoxide dismutase mimetic, on zymosan-induced nonseptic shock.
Topics: Animals; Disease Models, Animal; Immunohistochemistry; Intestines; Lipid Peroxidation; Lung; Male; Multiple Organ Failure; Organometallic Compounds; Probability; Protective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Risk Assessment; Sensitivity and Specificity; Shock; Statistics, Nonparametric; Superoxide Dismutase; Zymosan | 2004 |
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.
Topics: Animals; Lipid Peroxidation; Male; Mice; Multiple Organ Failure; Nitric Oxide; Nitrosation; Rosiglitazone; Shock; Thiazolidinediones; Zymosan | 2004 |
Hyperbaric oxygen therapy prevents vascular derangement during zymosan-induced multiple-organ-failure syndrome.
Topics: Analysis of Variance; Animals; Aorta; Endothelium, Vascular; Hyperbaric Oxygenation; Immunohistochemistry; Male; Malondialdehyde; Multiple Organ Failure; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Random Allocation; Rats; Rats, Sprague-Dawley; Tyrosine; Vascular Diseases; Vasodilation; Zymosan | 2004 |
Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice.
Topics: Acute Disease; Amides; Animals; Glycoside Hydrolases; Interleukin-1; Male; Malondialdehyde; Mice; Mice, Inbred Strains; Multiple Organ Failure; Peritonitis; Peroxidase; Shock, Septic; Tannins; Tumor Necrosis Factor-alpha; Zymosan | 2004 |
Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome.
Topics: Animals; Cytokines; Escherichia coli; Interferon-gamma; Interleukins; Kidney; Lipopolysaccharides; Liver; Lung; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Peritonitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation; Zymosan | 2004 |
Role of 5-lipoxygenase in the multiple organ failure induced by zymosan.
Topics: Animals; Arachidonate 5-Lipoxygenase; Lipid Peroxidation; Male; Mice; Mice, Knockout; Models, Animal; Multiple Organ Failure; Nitric Oxide; Peritonitis; Random Allocation; Syndrome; Zymosan | 2004 |
Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation; Zymosan | 2004 |
Chemiluminescence: comparison of whole blood with isolated polymorphonuclear leukocytes after major trauma.
Topics: Case-Control Studies; Cell Separation; Disease Progression; Humans; Inflammation; Injury Severity Score; Luminescent Measurements; Macrophage-1 Antigen; Multiple Organ Failure; Multiple Trauma; NADP; Neutrophil Activation; Neutrophils; Patient Selection; Predictive Value of Tests; Reactive Oxygen Species; Respiratory Burst; Respiratory Distress Syndrome; Risk Factors; Statistics, Nonparametric; Tetradecanoylphorbol Acetate; Time Factors; Zymosan | 2004 |
Increased activity of the intestinal mucosal mast cells in rats with multiple organ failure.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Fluorometry; Histamine; Immunohistochemistry; Intestinal Mucosa; Multiple Organ Failure; Rats; Tumor Necrosis Factor-alpha; Zymosan | 2004 |
Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.
Topics: Animals; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Pentoxifylline; Random Allocation; Survival Analysis; Vasodilator Agents; Zymosan | 2005 |
The effects of selective nitric oxide synthase blocker on survival, mesenteric blood flow and multiple organ failure induced by zymosan.
Topics: Animals; beta-Glucans; Enzyme Inhibitors; Guanidines; Kidney; Liver; Lung; Mice; Multiple Organ Failure; Nitric Oxide Synthase; Splanchnic Circulation; Spleen; Survival Analysis; Zymosan | 2005 |
Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?
Topics: Animals; Disease Models, Animal; Immunologic Factors; Mice; Multiple Organ Failure; Pentoxifylline; PPAR gamma; Prostaglandin D2; Vasodilator Agents; Zymosan | 2005 |
Altered chemokine response in an animal model of multiple organ dysfunction syndrome induced by zymosan.
Topics: Animals; Ascitic Fluid; Bronchoalveolar Lavage Fluid; Chemokine CCL2; Chemokines; Disease Models, Animal; Injections, Intraperitoneal; Male; Multiple Organ Failure; Peritonitis; Random Allocation; Rats; Rats, Sprague-Dawley; Zymosan | 2005 |
Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells.
Topics: Animals; Dose-Response Relationship, Drug; Histamine; Hormones; In Vitro Techniques; Intestinal Mucosa; Intestines; Male; Mast Cells; Microscopy, Electron; Multiple Organ Failure; Peptides; Polymerase Chain Reaction; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Time Factors; Tumor Necrosis Factor-alpha; Zymosan | 2005 |
The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock.
Topics: Analysis of Variance; Animals; Animals, Outbred Strains; Immunohistochemistry; Immunologic Factors; Male; Mice; Multiple Organ Failure; Nitric Oxide; Peroxynitrous Acid; PPAR gamma; Prostaglandin D2; Random Allocation; Zymosan | 2005 |
[Relationship between glomerular lesion and NF-kappaB p65 activity in rat multiple organ failure caused by zymosan].
Topics: Animals; Female; Hydrogen-Ion Concentration; Immunohistochemistry; Kidney Glomerulus; Multiple Organ Failure; Oxygen; Rats; Rats, Wistar; Transcription Factor RelA; Zymosan | 2005 |
Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure.
Topics: Acute Disease; Adenoviridae; Animals; Bacterial Infections; Dose-Response Relationship, Immunologic; Gene Expression; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Immunotherapy, Active; Interleukin-10; Interleukin-6; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Models, Animal; Multiple Organ Failure; Polysaccharides, Bacterial; Recombinant Fusion Proteins; Survival Rate; Transduction, Genetic; Tumor Necrosis Factor-alpha; Zymosan | 2006 |
A comparison of elderly and adult multiple organ dysfunction syndrome in the rat model.
Topics: Aging; Animals; Apoptosis; Body Weight; Bronchoalveolar Lavage Fluid; Calcium; Carbon Dioxide; Cytokines; Disease Models, Animal; Lung; Macrophages, Alveolar; Male; Multiple Organ Failure; Myocardium; Organ Size; Oxygen; Partial Pressure; Rats; Rats, Sprague-Dawley; Zymosan | 2006 |
Protective effect of Hypericum perforatum in zymosan-induced multiple organ dysfunction syndrome: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity.
Topics: Animals; Hypericum; Immunohistochemistry; Intestines; Lung; Male; Mice; Multiple Organ Failure; Neutrophils; Nitric Oxide; Nitric Oxide Synthase Type II; Plant Extracts; Zymosan | 2007 |
Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity.
Topics: C-Reactive Protein; Calcimycin; Calcitonin; CD18 Antigens; Humans; Hydrogen Peroxide; Interleukin-6; Leukocyte Count; Middle Aged; Multiple Organ Failure; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Opsonin Proteins; Phagocytosis; Protein Precursors; Sepsis; Severity of Illness Index; Shock, Septic; Syndrome; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; Zymosan | 2006 |
Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.
Topics: Animals; Blood Coagulation Disorders; Hyperbaric Oxygenation; Male; Multiple Organ Failure; Random Allocation; Rats; Rats, Sprague-Dawley; Survival Analysis; Zymosan | 2006 |
Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan.
Topics: Animals; Apoptosis; Fas Ligand Protein; Inflammation; Intestines; Kidney; Lipid Peroxidation; Mice; Mice, Knockout; Multiple Organ Failure; Neutrophil Infiltration; Nitric Oxide; PPAR alpha; Shock; Tumor Necrosis Factor-alpha; Tyrosine; Up-Regulation; Zymosan | 2006 |
Beneficial effects of erythropoietin in preclinical models of shock and organ failure.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Endotoxemia; Erythropoietin; Mice; Multiple Organ Failure; Shock; Shock, Hemorrhagic; Shock, Septic; Spinal Cord Injuries; Treatment Outcome; Zymosan | 2007 |
[Implications of lung interstitial dendritic cells of mice in multiple organ dysfunction syndrome].
Topics: Animals; Antigens, CD; B7-1 Antigen; B7-2 Antigen; CD11c Antigen; CD4-CD8 Ratio; Cell Proliferation; Chemokine CCL21; Dendritic Cells; Disease Models, Animal; Lectins, C-Type; Male; Mice; Mice, Inbred C57BL; Minor Histocompatibility Antigens; Multiple Organ Failure; Random Allocation; Receptors, CCR7; Receptors, Cell Surface; Zymosan | 2007 |
Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; bcl-2-Associated X Protein; Etanercept; Fas Ligand Protein; Immunoglobulin G; Inflammation; Mice; Mice, Knockout; Multiple Organ Failure; Peritonitis; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zymosan | 2008 |
Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Gene Deletion; Interleukin-10; Interleukin-1beta; Kidney; Lipid Peroxidation; Liver; Mice; Mice, Knockout; Multiple Organ Failure; Neutrophil Infiltration; Nitrates; Nitrites; Pancreas; Peritonitis; Tumor Necrosis Factor-alpha; Zymosan | 2008 |
Volatile anesthetic modulation of lung injury and outcome in a murine model of multiple organ dysfunction syndrome.
Topics: Anesthetics, Inhalation; Animals; Disease Models, Animal; Mice; Multiple Organ Failure; Peroxidase; Respiratory Distress Syndrome; Treatment Outcome; Zymosan | 1995 |
Deficiency of complement factor C5 reduces early mortality but does not prevent organ damage in an animal model of multiple organ dysfunction syndrome.
Topics: Aging; Animals; Complement Activation; Complement C5; Disease Models, Animal; Injections, Intraperitoneal; Male; Mice; Multiple Organ Failure; Organ Size; Zymosan | 1995 |
[Evaluation of an experimental model of multiple organ dysfunction].
Topics: Animals; Disease Models, Animal; Lung; Male; Multiple Organ Failure; Organ Size; Rats; Rats, Wistar; Survival Rate; Tomography, X-Ray Computed; Zymosan | 1994 |
The gut: a cytokine-generating organ in systemic inflammation?
Topics: Analysis of Variance; Animals; Bacterial Translocation; Cytokines; Intestinal Mucosa; Intestines; Male; Multiple Organ Failure; Rats; Rats, Sprague-Dawley; Zymosan | 1995 |
Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome.
Topics: Animals; Cytokines; Disease Models, Animal; In Vitro Techniques; Inflammation; Interleukin-1; Interleukin-6; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Tumor Necrosis Factor-alpha; Zymosan | 1996 |
Aprotinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model.
Topics: Animals; Aprotinin; Capillary Permeability; Disease Models, Animal; Endotoxins; Escherichia coli; Female; Femoral Artery; Heart; Hemodynamics; Hemorrhage; Hemostatics; Kidney; L-Lactate Dehydrogenase; Leukocyte Count; Liver; Lung; Multiple Organ Failure; Neutrophils; Serine Proteinase Inhibitors; Sheep; Wounds and Injuries; Zymosan | 1996 |
Increasing cytotoxic activity and production of reactive oxygen and nitrogen intermediates by peritoneal macrophages during the development of multiple organ dysfunction syndrome in mice.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Disease Models, Animal; Inflammation; Macrophage Activation; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Nitric Oxide; Phagocytosis; Superoxides; Syndrome; Zymosan | 1996 |
Organ damage is preceded by changes in protein extravasation in an experimental model of multiple organ dysfunction syndrome.
Topics: Animals; Body Fluid Compartments; Body Temperature; Body Weight; Capillary Permeability; Disease Models, Animal; Extracellular Space; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Proteins; Zymosan | 1997 |
Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chemokine CCL3; Chemokine CCL4; Chemotactic Factors; Complement C5a; Female; Heart Diseases; Liver Diseases; Lung Diseases; Lymphatic Diseases; Macrophage Inflammatory Proteins; Male; Mice; Mice, Knockout; Multiple Organ Failure; Syndrome; Zymosan | 1996 |
Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice.
Topics: Animals; Clodronic Acid; Drug Carriers; Liposomes; Macrophages; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Zymosan | 1997 |
Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects.
Topics: Animals; Benzamides; Carrageenan; Cell Movement; Edema; Enzyme Inhibitors; Histocytochemistry; Inflammation; Lung; Male; Mice; Mice, Knockout; Multiple Organ Failure; Neutrophils; Peritonitis; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Rats, Wistar; Zymosan | 1997 |
Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide.
Topics: Acute Disease; Animals; Disease Models, Animal; Enzyme Induction; Injections, Intraperitoneal; Male; Multiple Organ Failure; Nitric Oxide; Nitric Oxide Synthase; Peritonitis; Random Allocation; Rats; Rats, Sprague-Dawley; Zymosan | 1997 |
Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Disease Models, Animal; Disease Progression; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Survival Rate; Time Factors; Zymosan | 1997 |
Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Prospective Studies; Random Allocation; Tumor Necrosis Factor-alpha; Zymosan | 1998 |
Multiple organ failure (MOF) after severe trauma--a sheep model.
Topics: Albumins; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Disease Models, Animal; Disease Progression; Endotoxins; Female; Femur; Fracture Fixation, Intramedullary; Heart Function Tests; Least-Squares Analysis; Leukocyte Count; Liver; Lung; Multiple Organ Failure; Multiple Trauma; Sheep; Shock; Zymosan | 1998 |
Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS).
Topics: Animals; Disease Models, Animal; Disease Progression; Interleukin-10; Male; Mice; Mice, Inbred ICR; Multiple Organ Failure; Specific Pathogen-Free Organisms; Survival Analysis; Zymosan | 1998 |
A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.
Topics: Animals; Antibodies, Monoclonal; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Survival Analysis; Tumor Necrosis Factor-alpha; Zymosan | 1998 |
Role of interleukin-6 in a non-septic shock model induced by zymosan.
Topics: Animals; Antibodies, Monoclonal; Ascites; Ascitic Fluid; DNA Damage; Energy Metabolism; Injections, Intraperitoneal; Interleukin-6; Intestine, Small; Leukocyte Count; Lipid Peroxidation; Liver; Lung; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Organ Failure; NAD; Neutrophils; Nitrates; Nitrites; Oxidative Phosphorylation; Peritonitis; Peroxidase; Shock; Tyrosine; Zymosan | 1999 |
Protective effect of N-acetylcysteine on multiple organ failure induced by zymosan in the rat.
Topics: Acetylcysteine; Animals; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Free Radical Scavengers; Leukocyte Count; Male; Multiple Organ Failure; Nitrates; Nitric Oxide; Peritonitis; Random Allocation; Rats; Rats, Sprague-Dawley; Shock, Septic; Survival Analysis; Time Factors; Zymosan | 1999 |
Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat.
Topics: Animals; Benzamides; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Multiple Organ Failure; Niacinamide; Nitrates; Peritonitis; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Zymosan | 1999 |
Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cytokines; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Hemorrhage; Humans; Hypothermia; Interleukin-10; Lipopolysaccharides; Liver; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Recombinant Proteins; Spleen; Tumor Necrosis Factor-alpha; Zymosan | 1999 |
Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice.
Topics: Animals; Chemokine CCL3; Chemokine CCL4; Complement Activation; Complement C3; Complement C5; Disease Models, Animal; Exudates and Transudates; Injections, Intraperitoneal; Kidney; Leukocyte Count; Lung; Macrophage Inflammatory Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Mice, Mutant Strains; Multiple Organ Failure; Myocardium; Neutrophil Infiltration; Peritonitis; Spleen; Transaminases; Zymosan | 1999 |
Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat.
Topics: Animals; Hyperbaric Oxygenation; Lipid Peroxidation; Male; Malondialdehyde; Multiple Organ Failure; Peritonitis; Peroxidase; Rats; Rats, Sprague-Dawley; Tyrosine; Zymosan | 2000 |
A comparison of neonatal and adult multiorgan failure in a rat model.
Topics: Age Factors; Animals; Animals, Newborn; Disease Models, Animal; Disease Progression; Kidney; Liver; Lung; Male; Multiple Organ Failure; Organ Size; Rats; Rats, Sprague-Dawley; Spleen; Surgical Procedures, Operative; Zymosan | 2000 |
The role of tumor necrosis factor in the development of multiple organ failure in a murine model.
Topics: Animals; Bronchoalveolar Lavage Fluid; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Zymosan | 2000 |
Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adrenergic alpha-Agonists; Animals; Blood Pressure; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Glomerular Filtration Rate; Heart Rate; Hemodynamics; Male; Multiple Organ Failure; Norepinephrine; Phosphodiesterase Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Circulation; Splanchnic Circulation; Vascular Resistance; Zymosan | 2001 |
Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat.
Topics: Analysis of Variance; Animals; Cyclic N-Oxides; Free Radical Scavengers; In Vitro Techniques; Intestine, Small; Liver; Lung; Male; Multiple Organ Failure; Poly(ADP-ribose) Polymerases; Random Allocation; Rats; Rats, Sprague-Dawley; Spin Labels; Statistics, Nonparametric; Tyrosine; Zymosan | 2001 |
Tempering the temptation to treat with tempol.
Topics: Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Humans; Multiple Organ Failure; Rats; Shock, Septic; Spin Labels; Zymosan | 2001 |
Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan.
Topics: Animals; Enzyme Inhibitors; Exudates and Transudates; Guanidines; Lipid Peroxidation; Liver; Lung; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Multiple Organ Failure; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Peritonitis; Peroxidase; Poly(ADP-ribose) Polymerases; Rhodamines; Shock; Tyrosine; Zymosan | 2001 |
The involvement of multiple protease-antiprotease systems and gut origin sepsis in zymosan-associated endothelial barrier injury and multiple organ dysfunction in rats.
Topics: Animals; Bacterial Translocation; Body Fluids; Dose-Response Relationship, Drug; Endopeptidases; Endothelium; Injections, Intraperitoneal; Male; Multiple Organ Failure; Permeability; Protease Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; Zymosan | 2001 |
[Protective effects of tongli gongxia herbs on gut barrier in rat with multiple organ dysfunction syndrome].
Topics: Amine Oxidase (Copper-Containing); Animals; Bacterial Translocation; Drugs, Chinese Herbal; Endotoxins; Female; Male; Multiple Organ Failure; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Zymosan | 2000 |
Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Liver; Lung; Lymphotoxin-alpha; Mice; Mice, Knockout; Multiple Organ Failure; Organ Size; Spleen; Tumor Necrosis Factor-alpha; Zymosan | 2002 |
The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat.
Topics: Animals; Enzyme Inhibitors; Male; Models, Animal; Multiple Organ Failure; Nitric Oxide; Peritonitis; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Tyrphostins; Zymosan | 2002 |
Superoxide dismutase and catalase in an experimental model of multiple organ failure.
Topics: Animals; Catalase; Disease Models, Animal; Free Radical Scavengers; Lipid Peroxidation; Male; Multiple Organ Failure; Rats; Rats, Inbred Strains; Superoxide Dismutase; Zymosan | 1992 |
[Rat multiple organ failure model caused by zymosan injections: a pathomorphological study].
Topics: Animals; Disease Models, Animal; Male; Microscopy, Electron; Multiple Organ Failure; Rats; Rats, Inbred Strains; Reference Standards; Zymosan | 1991 |
[Pathological changes in immune defense system of multiple-organ failure rat and their action on pathogenesis].
Topics: Animals; Fibronectins; Male; Multiple Organ Failure; Phagocytes; Rats; Rats, Inbred Strains; Spleen; Thymus Gland; Zymosan | 1991 |
Does selective decontamination of the gastrointestinal tract prevent multiple organ failure? An experimental study.
Topics: Animals; Digestive System; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Lymph Nodes; Male; Mesentery; Multiple Organ Failure; Peritonitis; Rats; Rats, Inbred Strains; Streptomycin; Survival Rate; Trimethoprim; Zymosan | 1991 |
Protein malnutrition predisposes to inflammatory-induced gut-origin septic states.
Topics: Animals; Bacteria; Blood; Female; Infections; Inflammation; Intestinal Mucosa; Intestines; Liver; Male; Mice; Multiple Organ Failure; Protein-Energy Malnutrition; Respiratory Distress Syndrome; Spleen; Time Factors; Zymosan | 1990 |
SOD in rat models of shock and organ failure.
Topics: Animals; Body Weight; Cattle; Disease Models, Animal; Lipid Peroxidation; Liver; Male; Multiple Organ Failure; Peritonitis; Rats; Rats, Inbred Strains; Shock; Shock, Septic; Superoxide Dismutase; Zymosan | 1990 |
Neutrophil function and lipid peroxidation in a rat model of multiple organ failure.
Topics: Alanine Transaminase; Animals; Lipid Peroxides; Liver; Lung; Male; Multiple Organ Failure; Neutrophils; Organ Size; Rats; Rats, Inbred Strains; Superoxides; Zymosan | 1989 |
Development of a bacteria-independent model of the multiple organ failure syndrome.
Topics: Animals; Bacteria; Disease Models, Animal; Hemodynamics; Intestines; Kidney; Liver; Lung; Lymph Nodes; Mineral Oil; Multiple Organ Failure; Rats; Rats, Inbred Strains; Respiration; Sepsis; Zymosan | 1989 |
Endotoxin does not play a key role in the pathogenesis of multiple organ failure. An experimental study.
Topics: Animals; Body Temperature; Body Weight; Endotoxins; Escherichia coli; Hemorrhage; Lung; Lung Diseases; Male; Mice; Mice, Inbred C3H; Multiple Organ Failure; Organ Size; Spleen; Staphylococcus; Zymosan | 1989 |
Leukocyte induced pulmonary damage using intraperitoneal zymosan.
Topics: Animals; Cell Aggregation; Injections, Intraperitoneal; Leukocytes; Lung; Lung Diseases; Malondialdehyde; Multiple Organ Failure; Rabbits; Vitamin E; Zymosan | 1989 |
Complement activation in peritonitis. Association with hepatic and renal perfusion abnormalities. First place winner: Conrad Jobst award.
Topics: Animals; Complement Activation; Elapid Venoms; Female; Liver Circulation; Male; Multiple Organ Failure; Peritonitis; Rats; Rats, Inbred Strains; Renal Circulation; Time Factors; Vascular Resistance; Zymosan | 1987 |
Multiple-organ failure and sepsis without bacteria. An experimental model.
Topics: Animals; Blood Chemical Analysis; Disease Models, Animal; Germ-Free Life; Leukocyte Count; Male; Multiple Organ Failure; Organ Size; Paraffin; Rats; Rats, Inbred Strains; Zymosan | 1986 |
Polydatin: a new therapeutic agent against multiorgan dysfunction.
Topics: Animals; Caspase 3; Cytokines; Female; Glucosides; Multiple Organ Failure; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Stilbenes | 2015 |
[Pharmacological intervention in experimental multiple organ failure in rats].
Topics: Allopurinol; Animals; Antioxidants; Free Radicals; Fructose-Bisphosphatase; Glucosides; Glutathione Peroxidase; Male; Malondialdehyde; Multiple Organ Failure; Oxygen; Rats; Rats, Inbred Strains; Stilbenes; Superoxide Dismutase | 1992 |